Business UpdateApr 30, 2026, 04:19 PM
CELU Effects 1-for-10 Reverse Stock Split; Details Business Strategy
AI Summary
Celularity Inc. detailed its business strategy and operations in its annual 10-K filing, highlighting its focus on advancing health longevity through placental-derived allogeneic cellular therapies and advanced biomaterial products. The company also disclosed that it effected a 1-for-10 reverse stock split of its outstanding Class A common stock on February 28, 2024. Celularity continues to expand its biomaterials pipeline and leverage its integrated Celularity IMPACT platform for manufacturing and contract development services.
Key Highlights
- CELU effected a 1-for-10 reverse stock split of Class A common stock on February 28, 2024.
- Developing off-the-shelf placental-derived allogeneic cellular therapies for age-related degenerative diseases.
- Commercializing advanced biomaterial products including Biovance, Biovance 3L, Interfyl, CentaFlex, and Rebound.
- Leveraging Celularity IMPACT platform for integrated manufacturing in a 147,215 sq ft cGMP-ready facility.
- Advancing pipeline with investigational biomaterial products: Celularity Tendon Wrap, Fuse Bone Void Filler, and Celularity Placental Matrix.
- Entered amended sublicense with BioCellgraft, Inc. in December 2025 for dental and oral healthcare products.
- Collaborated with Defeye, Inc. in October 2025 for ophthalmic biomaterial applications in Florida.
- Provides fee-based biobanking services for umbilical cord blood and placenta-derived cells and tissue.